Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

European shares rose on Thursday as lower-than-expected U.S. inflation strengthened hopes for Federal Reserve interest rate ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from injectable versions of GLP-1 drugs, the company ...

Novo Nordisk (NVO) stock gains as the company files for FDA approval of CagriSema, its next-gen obesity drug which causes up ...

Novo Nordisk said on Thursday it filed a marketing application to the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

U.S. President Donald ​Trump ⁠in July sent letters to 17 drugmakers urging them to slash prices. Pfizer and AstraZeneca first ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

European shares were muted on Thursday as investors adopted a largely cautious stance ahead of a series of central bank ...